Biopharmaceutical News Week # 22.2017
Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com
Manchester, London, Egypt, Manilla. Coward terrorist attacks once again. We are mourning with our friends and readers around the globe.
Special Report
Highlights from the Meeting
A combination of Merck’s Keytruda, a PD-1 checkpoint inhibitor, and Incyte’s endocadostat, an indolamine 2,3-dioxygenase 1 (IDO1) enzyme inhibitor showed an overall response rate in second-line non-small cell lung cancer which was almost twice as high as Keytruda alone.
A combination of Bristol-Myers Squibb’s Opdivo, a PD-1 checkpoint inhibitor and Yervoy, a CTLA4 inhibitor slowed mesothelioma progression more than Opdivo alone.
Johnson & Johnson reported that a combination of Zytiga with prednisone and androgen deprivation was superior to androgen deprivation at improving survival among patients with high-risk metastatic hormone-naïve prostate cancer.
Roche’s combination of Herceptin with Perjeta to treat post-surgery breast cancer progression was rather disappointed and only 1% higher than Herceptin alone.
AstraZeneca’s Lynparza, a PAPR inhibitor, reduced the risk of breast cancer worsening or death by 42% in a phase 3 study, with a shrinking of tumors in about 60% of patients versus 29% in the ones treated with chemotherapy.
Pfizer’s dacomitinib, was superior to AstraZeneca’s Iressa in delaying EGFR-positive lung cancer, in newly diagnosed patients, in reducing the risk of progression by 41% but was inferior to Roche’s Tarceva.
Eisai reported that Lenvima doubled median progression-free survival time at 7.4 months compared with Bayer Nexavar’s 3.7 months.
Dendreon showed that Provenge, its prostate cancer vaccine generates a killer T-cell response and that the sternght of the response correlates with overall survival.
Juno Therapeutics reported that JCAR017, its CAR-T cell therapy, had positive results on early-stage non-Hodgkin lymphoma with a combined overall response rate of 86% and a complete response rate of 59% (26 out of 44 patients, with 37 out of 38 still alive).
Novartis reports positive response rate in mid-stage lymphoma study with CTL019, a CAR-T cell therapy candidate with nevertheless prevalent side effects. The best overall response rate (OOR) was 59% including 43% complete responders. Globally the ORR was 45% including 37% of complete responders with 57% of patients experiencing cytokine release syndrome a known complication of CAR-T therapy.
Nanjing Legend Biotech (China) released data of its own CAR-T clinical candidate showing positive results to treat relapsed or refractory multiple myeloma.
Sanofi and Regeneron report first results with REGN2810, a PD-1 checkpoint inhibitor, in patients with cutaneous squamous cell carcinoma – the second deadliest form of skin cancer behind melanoma- with an overall response rate of 46;2% (12 in 26 patients) including 2 complete responses and 9 partial responses.
Hutchinson China MediTech reports positive results with fruquinitib in colon cancer and is working on a fast approval in China. Overall survival rate was 9.3 months versus 6.57 months in the placebo arm. The median progression-free survival rate hit 3.71 months compared to 1.84 months for the control group. Chi-Med CEO Christian Hogg indicated, a few months ago, that this is the first time a Chinese biotech has discovered and developed a drug for the Chinese market.
A few days ago, the US FDA had granted approval for Merck’s Keytruda to fight tumors with a biomarker called microsatelillte instability-high or mismatch repair deficient. “Until now, the FDA has approved cancer treatments based on where in the body the cancer started — for example, lung or breast cancers. We have now approved a drug based on a tumor’s biomarker without regard to the tumor’s original location” said Richard Pazdur acting director of the office of hematology and oncology products in the FDA’s CDER and director of the FDA’s Oncology Center of Excellence.
Following the same pathway, Loxo Oncology reported data with larotrectinib (LOXO-101), a tropomyosin receptor kinase (TRK) biomarker-specific drug, which could treat an array of cancer in various sites of the body. Loxo Oncology already showed a number of cases where children and adults with TRK fusion cancer responded to the larotrectinib
IBM introduced new data showing its Watson supercomputer agreed with doctors on a treatment course for a range of cancers up to 96% of the time.
Bioevents
BIO International Convention on June 19-22 in San Diego (USA)
5thAntibody Industrial Symposium, on June 27-28, in Tours (France)
MedFIT on June 28-29 in Grenoble (France)
Nordic Life Science Days (NLS) 2017 on September 12-14 in Malmö-Copenhagen (Sweden and Denmark)
BIOPharm America on September 26-27 in Boston (USA)
BIO Latin America on October 26-28 in Sao Paulo (Brazil)
BIO Europe on November 6-8 in Berlin (Germany)
World Congress on Biomedical Engineering 2017 on November 9-11 in Xian (China)
BIOFIT on November 28-29 in Strasbourg (France)
http://btobioinnovation.com/events/pharma-biotech-events/
http://btobioinnovation.com/events/in-vitro-diagnostic-events/
This document has been prepared by btobioinnovation and is provided to you for information purposes only. The information contained in this document has been obtained from sources that btobioinnovation believes are reliable but btobioinnovation does not warrant that it is accurate or complete. The views presented in this document are those of btobioinnovation’s editor at the time of writing and are subject to change. btobioinnovation has no obligation to update its opinions or the information in this document.
Last News
- Note de réflexion de fin d’année
- EMA re-examines its opinion and approves Leqembi for the treatment of Alzheimer’s disease
- Le déclassement de la France
Events
News archives
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- March 2024
- February 2024
- January 2024
- November 2023
- September 2023
- July 2023
- April 2023
- March 2023
- January 2023
- December 2022
- November 2022
- October 2022
- August 2022
- June 2022
- May 2022
- April 2022
- March 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- October 2018
- June 2018
- May 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- September 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- June 2014
- May 2014
- April 2014
- March 2014
- January 2014
- November 2013
- September 2013
- July 2013
- May 2013
- April 2013
- March 2013
- January 2013
- December 2012
- November 2012
- October 2012
- March 2012